By Jeff Williamson THE SITUATION: A medical device company was preparing to launch a novel product used in interventional cardiac surgeries — one that offered improved performance, simplified clinical workflows, and reduced procedure times. The company asked RNA to help it quantify the benefits of the new device in light of direct cost savings, workflow streamlining,
THE PROBLEM: A publicly traded clinical stage biotech company needed to understand the correct implied discount rate for a lease agreement in accordance with ASC 842 rules. THE SOLUTION: ASC 842 has specific rules relating to leases, including guidance on lease classification (operating versus financial) and how to discount a lessee’s lease payments to arrive
THE PROBLEM: A medtech start-up with a leading CE-marked product faced a strategic resource allocation decision: invest in next-generation technology in the current low-growth market, or place bets on riskier technologies in the emerging higher growth segment? THE SOLUTION: RNA undertook a comprehensive strategic and commercial operations review, including market segmentation, competitive analysis, assessment of
THE PROBLEM: Publicly traded late-stage therapeutics company negotiates with, and enters into, collaboration / license arrangement with a big pharma partner. THE SOLUTION: Forecasting, market research, modeling and transaction support combined with resultant collaboration agreement accounting analyses. “You were a great support for us, responsive and knowledgeable. Thank you!” CFO “You are my top go